Madam Speaker, I move to suspend the rules and pass the bill (H.R. 6344) to provide emergency authority to delay or toll judicial proceedings in United States district and circuit courts, and for…
Madam Speaker, I move to suspend the rules and pass the bill (H.R. 6344) to provide emergency authority to delay or toll judicial proceedings in United States district and circuit courts, and for other purposes.
Madam Speaker, I ask unanimous consent that all Members have 5 legislative days to revise and extend their remarks and include extraneous material.
Madam Speaker, I yield myself such time as I may consume.
(Mr. CONYERS asked and was given permission to revise and extend his remarks.)
Madam Speaker, I rise in support of H.R. 6344, the Responsive Government Act of 2008, bipartisan legislation with strong support on both s des of the aisle.
The bill consists of three major components, each of which has, in substance, previously passed the House on the suspension calendar.
Section 2 of the bill takes into account the practical realities of a natural disaster or other emergency situation where compliance with filing deadlines or other court rules would be impracticable, dangerous, or simply impossible.
In emergency situations, such as those which occurred during, and in the aftermath of, Hurricane Katrina, this section of the bill would provide the Chief Judge of the affected District Court or Court of Appeals with the authority to excuse a failure of litigants or the U.S. Government to comply with filing deadlines.
Section 3 grants similar authority to the Patent and Trademark Office to excuse failures to comply with filing deadlines caused by a natural disaster or other emergency.
Section 4 of the bill also involves a grant of authority to the Director of the Patent and Trademark Office to excuse specific late filings--this time, in connection with unintentional human error.
Section 4 would provide the USPTO with the authority to accept an application for patent term restoration under the Hatch-Waxman Act if that application is filed within 3 business days of the existing 60-day deadline.
This small but important change simply gives the USPTO discretion to accept a late application, within a limited time period, under specific conditions. This change is both good patent policy and good for public health.
Under current law, the 60-day deadline is absolutely rigid, and the consequences of that rigidity can be draconian and harshly disproportionate.
Up to 5 years of patent protection can be destroyed on account of a minor, inadvertent filing error of as little as 1 day.
This penalty is not merely disproportionate and excessive, it is also out of sync with most other patent laws and regulations, which typically give the USPTO Director the authority to excuse minor errors.
For instance, currently, if an applicant files an incomplete Hatch- Waxman application, the USPTO can grant up to 2 extra months to correct the application.
H.R. 6344 would eliminate this dichotomy, bringing the deadline provision of Hatch-Waxman into greater harmony with other relevant patent laws and regulations.
Moreover, H.R. 6344 would save lives. The reality is that the unnecessary forfeit of years of patent rights for drugs can have an extremely damaging effect on patients.
When the existing rigid deadline operates to strip away up to 5 years of patent protection, it significantly reduces the likelihood of the research and innovation that a full patent term would encourage.
This is not just a theoretical problem. A small U.S. maker of Angiomax, a blood thinner, stands to lose 4\1/2\ years of patent protection as a result of inadvertently filing its Hatch-Waxman application for patent term restoration 1 day late.
Angiomax is considered the best alternative to heparin in coronary angioplasties, and shows great promise with respect to open heart surgery and the treatment of stroke and peripheral artery disease.
Public health and safety pushes us to promote effective substitutes for heparin, such as Angiomax.
Earlier this year, contamination problems in Chinese manufacturing plants, where heparin is made from pig intestines led to 81 patient deaths.
Even apart from problems of contamination, thousands of people die every year from adverse reactions to heparin.
At this moment, when the serious shortcomings of heparin have come into bold relief, we have rightfully turned our attention to adjusting a flawed patent provision in a manner that can improve and even save the lives of large numbers of sick patients for years to come in this and other instances.
Taken together, the three components of this bill--the discretion provided in cases of emergency and the discretion provided in the case of unintentional human error--are all sound public policy, and have justifiably attracted bipartisan backing.
This bill is not inconsistent with, nor does it detract from, other legal authorities.
I urge my colleagues to support this important legislation.
Madam Speaker, I am pleased now to yield such time as he may consume to the author of this measure, the gentleman from Massachusetts (Mr. Delahunt), who has worked tirelessly to make sure that this measure arrives on the floor for consideration today.
Madam Speaker, I yield myself such time as I may consume.
We are in a spirit of bipartisanship and we are reaching out. Let's not nationalize the oil companies. We agreed on that. Let's go from shale to coal and let's go into all the alternatives. We are all for that. No suing. Drill, drill, drill. No sue, no sue, no sue.
Now we are getting down to the 41 million acres of leased oil, and he knew I was going to bring that up, that have been unused, and I don't know how to make those oil companies drill and find out if there's anything there or not. Maybe they don't want to know. Maybe they do want to know but they don't have the machinery or equipment.
Maybe there's a technological problem that is beyond the understanding of we mere mortals on Judiciary.
Yes. The gentlemen yielded to me, so I will yield to him.
You know, we had a hearing on this subject. The oil execs of the five companies came before us. In the other body, three of them told us how much they made. As you know, they make the top profits of any executives in business, short of the pharmaceuticals, of course. I don't want to short them. We found out that two of them couldn't even remember how much they made.
Look; salaries, options, stock, bonus. Who knows what else. I hope my dear friend from California will join me on the letter that I am sending to the two, referring them to look up their accountant, because I know they paid their taxes on April 15, and just give us a ballpark figure of how much they made. If the gentleman will join me in this consideration, I'd be very grateful.
I yield to the gentleman from Massachusetts.
Madam Speaker, I yield such time as she may consume to the gentlewoman from the Virgin Islands (Mrs. Christensen), a leader in universal health care activities.
Madam Speaker, I yield back any time we have remaining.